As research continues to evolve, it is likely that we will see the development of new treatments that combine the benefits of GLP-1 receptor agonists with other mechanisms of action. The Ozempic click has set a new standard for patient care, and future treatments will likely be designed to be just as intuitive and easy to use.

"Pen splitting via click counting to save money is dangerous. I've seen patients inadvertently take 1.2 mg when they thought they were taking 0.5 mg because they used a click chart for the wrong pen. Always—always—verify which pen you have. The gold 2 mg pen's 18 clicks is 0.5 mg. The blue 1 mg pen's 18 clicks is 0.25 mg. Mix them up and you could end up in the ER with hypoglycemia."

Ozempic, also known as semaglutide, is a GLP-1 receptor agonist that mimics the action of the naturally occurring hormone GLP-1. GLP-1 is involved in glucose regulation, insulin secretion, and appetite control. Ozempic is designed to help adults with type 2 diabetes manage their blood sugar levels, improve glycemic control, and reduce the risk of major adverse cardiovascular events.

For the standard Ozempic pen (which delivers 2 mg per 1.5 mL of solution), the engineering is precise. However, the manufacturer (Novo Nordisk) designed the pen with pre-set dose markings (0.25 mg, 0.5 mg, 1.0 mg, or 2.0 mg depending on the pen version). The unmarked clicks in between are what patients refer to as the "clicks."